your numbers alcoholic are so far off its not even funny..Every single person alive will be tested at least a few times each in their life and some much more based on their family history and physical situation. The age category can start from around age 43 then go to every single person older.You do the math then get back to me. Millions and millions of test will be preformed and the insurance companies will love it because of pricing.
nice buying....story getting better
stock will open up higher tomorrow,up about .30 to .60 . Early buying will happen due to the % gain we had. those that found out why the pop today will buy tomorrow early if they like the story. after the higher open its a #$%$ shoot . we will know real early what direction it is headed.
UH OH....More pain
we need market help to go up huge...if market continues its downtrend today we will close higher but not up big.
I understand your frustration. In April, the Company announced the 6 month interim results from our spinal cord injury trial. The data was encouraging and we provided a high level overview of the data. The 12 month data from the same group of patients showed a declining trend in the magnitude of the effect in both strength and function at the twelve month time point. As you can imagine this generated some concern within the Company. While the results at twelve months were still improved from baseline, this late variability led the Company to conduct an earlier‑than‑planned interim analysis of the Cohort II data. We received this interim analysis on Friday May 27th. The results of this interim analysis, which were reviewed by the Company as well as by the IA-DMC, showed differences in motor strength that favored the treatment group, but the magnitude of the effect led both the Company and the IA-DMC to conclude that achieving the primary endpoint objective of the Pathway Study would be unlikely. Based upon these findings, the Company decided to terminate the study and close out operations.
One of the greatest risks in a clinical trial is the eventual clinical results. We saw a change in the strength of the results for the first open label cohort and very quickly convened a panel of industry experts, made the decision to perform an interim analysis and immediately following the receipt of that information released the news to the market. Unfortunately, this study was pivotal in proving the technology and platform. Without stronger results, the Company is unable to raise the required funding to continue our clinical efforts.
StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study
NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June.